EBV gp350-Ferritin Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

EBVEpstein-Barr Virus InfectionHerpesvirusInfectious Mononucleosis

Phase 1

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

Active, not recruitingNCT04645147

National Institute of Allergy and Infectious Diseases (NIAID)EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis

Start: 2022-03-29End: 2026-07-01Updated: 2025-07-17

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Active, not recruitingNCT05683834

National Institute of Allergy and Infectious Diseases (NIAID)Epstein-Barr Virus Infection, Herpesvirus, Infectious Mononucleosis

Start: 2023-09-22End: 2027-04-01Updated: 2025-11-21